Raymond James set a C$11.00 price target on Biosyent (CVE:RX) in a research report released on Thursday. The brokerage currently has an outperform rating on the stock.

Shares of RX opened at C$8.02 on Thursday. Biosyent has a twelve month low of C$6.93 and a twelve month high of C$10.26. The company has a market capitalization of $115.35 million and a price-to-earnings ratio of 21.22.

Biosyent (CVE:RX) last announced its quarterly earnings results on Wednesday, March 20th. The company reported C$0.11 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of C$0.11. The firm had revenue of C$5.91 million for the quarter, compared to analysts’ expectations of C$6.40 million. As a group, equities research analysts forecast that Biosyent will post 0.440000004282239 earnings per share for the current fiscal year.

Biosyent Company Profile

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.